A Clinical Study On Treatment Of HBV-related Cirrhosis With Yiqi Huoxue Ruangan Method

ObjectiveThrough the clinical study of Huoxue Ruangan Decoction in the treatment of HBV-related Cirrhosis,the efficacy and safety of Yiqi Huoxue Ruangan Method to anti-hepatic fibrosis were evaluated,in order to find an effective traditional Chinese medicine compound for the treatment of HBV-related cirrhosis.MethodsA randomized,controlled clinical study was used.The patients were selected according to the diagnostic criteria of hepatitis B cirrhosis and randomly divided into treatment group 90 cases and control group 60 cases according to the ratio of 2:1.The treatment group received Huoxue Ruangan Decoction combined with entecavir,and the control group received entecavir for 96 weeks.The changes of LSM,serum HBV DNA quantification,HBsAg clearance,HBeAg clearance and liver function before and after treatment were observed at 48W and 96W,and adverse reactions were observed.Resu ts1.In terms of liver stiffness measurement,there was no significant difference in the proportion of LSM decreased)3kPa after 48 weeks in the two groups(P>0.05),but after 96 weeks of treatment,there was a statistically significant difference in the proportion of LSM decreased)3kPa between the two groups(P<0.05).After 48 weeks of treatment,the LSM of the treatment group and the control group decreased by 4.71kPa and 3.68 kra,respectively.There was significant difference between the two groups(P<0.01,P<0.05),but there was no significant difference between the two groups.Statistical differences.After 96 weeks of treatment,the LSM of the treatment group and the control group decreased by 8.39kPa and 6.61kPa,respectively.There was significant difference between the two groups(P<0.01).There was significant statistical difference between the two groups(P<0.05).2.In terms of' liver function,the levels of ALT and AST in the two groups were significantly lower than those before treatment(P<0.01),and the ALB levels were significantly higher than those before treatment(P<0.01,P<0.01).The A/G levels in the treatment group were significantly higher than those before treatment at 48 and 96 weeks(P<0.05,P<0.01).There was no significant difference in A/G levels between the 48 weeks and 96 weeks after treatment.Differences(P<0.05,P<0.01).There was no statistically significant difference in ALT and AST between the two groups after 48 weeks of treatment.There was a statistically significant difference after 96 weeks of treatment(P<0.01,P<0.01);There were significant differences between the week and 96 weeks(P<0.01,P<0.01).The difference of A/G difference was statistically significant after 48 weeks and 96 weeks of treatment(P<0.05,P<0.01).In terms of HBV DNA clearance,the HBV DNA negative conversion rate of the treatment group and the control group was 68.42%(39/57)and 46.43%(13/28)after 48 weeks of treatment.There was no significant statistical difference between the two groups(P>0.05).After 96 weeks of treatment,the negative conversion rates of HBV DNA in the treatment group and the control group were 87.72%(50/57)and 67.86%(19/28),respectively.There was significant statistical difference between the two groups(P<0.01).4.In terms of HBsAg clearance,there was no statistical difference between the two groups after 48 weeks and 96 weeks of treatment.After 48 weeks of treatment,the levels of HBsAg in the treatment group and the control group decreased by 0.421g IU/ml and 0.131g IU/ml,respectively.There was significant difference between the treatment group and the treatment group(P<0.01).There was no significant statistical difference before the comparison,and there was no statistically significant difference between the groups.After 96 weeks of treatment,the serum HBsAg levels in the treatment group and the control group decreased by 0.991g IU/ml and 0.16 1g IU/ml,respectively.There was significant difference between the treatment group and the treatment group(P<0.01).There was no significant statistical difference before treatment,and there was significant statistical difference between the groups(P<0.05).5.In terms of HBeAg negative conversion,there was no significant difference between the two groups after 48 weeks and 96 weeks of treatment(P>0.05,P>0.05).6.No serious adverse reactions occurred during the 96 weeks treatment cycle,and no significant abnormalities were observed in the safety indicators.GonelusionYiqi Huoxue Ruangan Method has certain anti-hepatic fibrosis,inhibits HBV replication and improves liver function.It has the tendency of time-dependence with the treatment efficacy,and has no obvious adverse reactions.